Please type a plus sign (+) inside this box →

OIPE 33 JUN 25 2001 PATENT & TRADEMARK OFFICE

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	09/814,558
Filing Date	March 22, 2001
First Named Inventor	Lazarus et al.
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	209897

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document: Application or Patent Number	U.S. Patent Document: Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
DL	AA	5,780,589		Lazarus et al. 530-331	07-14-98	11-30-94
DL	AB	5,811,400		Schiller 514/19	09-22-98	08-10-95

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document: Office	Foreign Patent Document: Application or Patent Number	Foreign Patent Document: Kind Code	Name of Patentee or Applicant	Date of Publication	Translation: Yes	Translation: No*+

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation: Yes	Translation: No*+
DL	AC	ABRASH et al., Biochemistry, 2(5):947-953, Sept.-Oct. (1963)		
	AD	ARAKAWA et al., Transplantation, 53(4): 951-953, April (1992)		
	AE	ARAKAWA et al., Transplantation Pro., 24(2):696-697, April (1992)		
	AF	ARAKAWA et al., Transplantation Pro., 25(1):738-740, February (1993)		
DL	AG	BALBONI et al., Biol. Chem., 378:19-29, January (1997)		

Examiner Signature	David Lester	Date Considered	9/27/01

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

\+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →

OIPE JUN 25 2001 PATENT & TRADEMARK OFFICE

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	09/814,558
Filing Date	March 22, 2001
First Named Inventor	Lazarus et al.
Group Art Unit	~~1645~~ 1653
Examiner Name	
Attorney Docket Number	209897

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Yes	Translation No*+
DL	AH	BORCH et al., J. Org. Chem., 37(10):1673-1674 (1972)		
	AI	BRYANT et al., Biol. Chem, 378:107-114, February (1997)		
	AJ	BRYANT et al., Trends in Pharmacol. Sci., 18: 42-46 (1998)		
	AK	CALLAGHAN et al., J. Biol. Chem., 268(21):16059-16064, July 25 (1993)		
	AL	CAPASSO et al., Int. J. Peptide Protein Res., 45:567-573 (1995)		
	AM	CARPENTER et al., J. Am. Chem. Soc., 116(19):8450-8458 (1994)		
	AN	CHAPPELL, Lancet, 343:556, March 5 (1994)		
	AO	CRABB et al., J. Chem. Soc., Perkins Transactions II, 370-378 (1977)		
	AP	CRESCENZI et al., Eur. J. Biochem., 247:66-73 (1997)		
	AQ	DYGOS et al., Synthesis, 741-743, August (1992)		
	AR	ERMISCH et al., Phys. Rev., 73(3):489-527, July (1993)		
	AS	FLIPPEN-ANDERSON et al., J. Peptide Res., 49:384-393 (1997)		
	AT	FORD et al., Cancer Research, 50:1748-1756, March 15 (1990)		
DL	AU	FROEHLICH et al., Alcohol Clin. Exp. Res., 20(8):181A-186A, November Supp. (1996)		
	AV	GUERRINI et al., Bioorg. Med. Chem., 6:57-62 (1998)		
	AW	HAYASHI et al., Chem. Pharm. Bull., 31(1):312-314 (1983)		
	AX	HOUSE et al., Neurosci. Lett., 198:119-122 (1995)		
	AY	JONES et al., J. of Pharm. Exp. Thera., 262(2):638-645 (1992)		
	AZ	KERTÉSZ et al., J. Labelled Cpd. and Radiopharm., XLI:1083-1091 (1998)		
	BA	LAZARUS et al., J. Biol. Chem., 264(1):354-362, January 5 (1989)		
	BB	LAZARUS et al., Biochem. Biophys. Res. Comm., 178(1):110-115, July 15 (1991)		
	BC	LAZARUS et al., Drug Devel. Today, 3(6):284-294, June 6 (1998)		
	BD	LAZARUS et al., Int'l Symp. on Peptide Chem. and Biol., Changchung, PRC (1999)		
	BE	LENSING et al., Neuropsychobiology, 31:16-23 (1995)		
	BF	LINNER et al., Eur. J. of Pharmacol., 354:R3-R5 (1998)		
	BG	MARSDEN et al., Int. J. Peptide Protein Res., 41:313-316 (1993)		
	BH	MATTHES et al., Nature, 383:819-823, October 31 (1996)		
DL	BI	MENKENS et al., Eur. J of Pharmacol., 219:345-346 (1992)		
	BJ	MOSBERG et al., Letters in Peptide Science, 1:69-72 (1994)		

Examiner Signature	David Lazar	Date Considered	9/27/01

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

\+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

JC133 JUN 25 2001 PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box +

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 3

Complete if Known	
Application Number	09/814,558
Filing Date	March 22, 2001
First Named Inventor	Lazarus et al.
Group Art Unit	~~1645~~ 1653
Examiner Name	
Attorney Docket Number	209897

RECEIVED JUN 27 2001 TECH CENTER 1600/2900

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Yes	Translation No*+
DL	BK	NOGAE et al., Biochem. Pharmacol., 38(3):519-527 (1989)		
	BL	PEARCE et al., Proc. Natl. Acad. Sci. USA, 86:5128-5132, July (1989)		
	BM	PORTOGHESE et al., Eur. J. Pharmacol., 146:185-186 (1988)		
	BN	RAMU et al., Int. J. Cancer, 43:487-491 (1989)		
	BO	SAGAN et al., Biochem. Biophys. Res. Commun., 187(3):1203-1210, September 30 (1992)		
	BP	SALVADORI, Mol. Med. 1(6):678-689, September (1995)		
	BQ	SALVADORI, J. Med. Chem., 42:5010-5019 (1999)		
	BR	SCHILLER et al., Proc. Natl. Acad. Sci. USA, 89:11871-11875, December (1992)		
DL	BS	SCHILLER et al., Peptides: Chemistry, Structure and Biology; Proceedings of the Thirteenth American Peptide Symposium, pp. 483-486, June 20-25 (1993), Edmonton, Alberta, Canada, ESCOM		
	BT	SCHILLER et al., J. Med. Chem., 36(21):3182-3187 (1993)		
	BU	SCHINKEL, et al., J. Clin. Invest., 97(11):2517-2524, June (1996)		
	BV	SCHINKEL, Intern. J. Clin. Pharm. Therapeutics, 36(1):9-13 (1998)		
	BW	TEMUSSI et al., Biochem. Biophys. Res. Commun., 198(3):933-939, February 15 (1994)		
DL	BX	JONKER et al., Br. J of Pharmacol., 127:43-50 (1999)		
DL	BY	ZAMORA et al., Mol. Pharmacol., 33:454-462 (1988)		

Examiner Signature	David Lieberman	Date Considered	9/27/01

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

\+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).